- Price
- $53.07
- Day
- +7.06%
- Mkt Cap
- $5.12B
- 52W Range
- $44.12 – $78.48
- Volume
- 2.14M
- Beta
- 1.70
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
CRSP reports a narrower-than-expected Q2 loss. Revenues beat estimates as Casgevy sales surge across global markets and clinical programs advance.
Read full article
ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026.
Read full article
CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.1. This compares to a loss of $1.29 per share a year ago.
Read full article
Analysts remain optimistic that the market will view upcoming catalysts in a bullish light.
Read full article
CRISPR Therapeutics recently won a key label expansion. The company has important data readouts on the horizon.
Read full article
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $48.44, moving +1.68% from the previous trading session.
Read full article
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
Read full article
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
In the most recent trading session, CRISPR Therapeutics AG (CRSP) closed at $46.54, indicating a -2.08% shift from the previous trading day.
Read full article
Ark Investment Management's high-profile stock picker Cathie Wood has bought stakes in CRISPR Therapeutics for a couple of the firm's funds. While it's typically considered a gene-editing play (and even named after the underlying genomic science), that's not all this biotechnology outfit is working on.
Read full article
CRISPR Therapeutics offers a diversified gene-editing pipeline, with CASGEVY as its lead approved asset and multiple upcoming catalysts. CRSP's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are imminent. CASGEVY's efficacy and expanding market access, combined with a robust cash position, underpin a favorable risk/reward at current levels.
Read full article
Amova Asset Management Americas Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ: CRSP) by 5.3% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,853,875 shares of the company's stock after selling 104,236 shares during the quarter. CRISPR
Read full article